Genmab A/S (GMAB) News Today $22.34 -0.10 (-0.45%) Closing price 04:00 PM EasternExtended Trading$22.34 0.00 (-0.02%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Japan approves Genmab’s EPKINLY for R/R follicular lymphoma treatmentFebruary 20 at 12:34 PM | markets.businessinsider.comGenmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care ConferenceFebruary 19 at 9:14 AM | globenewswire.comShort Interest in Genmab A/S (NASDAQ:GMAB) Decreases By 6.4%Genmab A/S (NASDAQ:GMAB - Get Free Report) was the target of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 1,620,000 shares, a decrease of 6.4% from the January 15th total of 1,730,000 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average daily volume of 1,370,000 shares, the days-to-cover ratio is currently 1.2 days.February 18 at 9:58 PM | marketbeat.comWhat is William Blair's Forecast for Genmab A/S Q3 Earnings?February 18 at 2:05 AM | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Shares Sold by DDD Partners LLCDDD Partners LLC decreased its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 61.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 226,074 shares of the company's stock after selling 357,0February 17, 2025 | marketbeat.comAnalysts Issue Forecasts for Genmab A/S Q3 EarningsFebruary 17, 2025 | americanbankingnews.comLeerink Partnrs Predicts Genmab A/S Q3 EarningsGenmab A/S (NASDAQ:GMAB - Free Report) - Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share estimates for Genmab A/S in a report issued on Thursday, February 13th. Leerink Partnrs analyst J. Chang anticipates that the company will post earnings of $0.43 per share forFebruary 17, 2025 | marketbeat.comResearch Analysts Issue Forecasts for Genmab A/S Q3 EarningsGenmab A/S (NASDAQ:GMAB - Free Report) - William Blair issued their Q3 2025 earnings per share (EPS) estimates for Genmab A/S in a research note issued on Thursday, February 13th. William Blair analyst M. Phipps anticipates that the company will earn $0.46 per share for the quarter. The consensusFebruary 17, 2025 | marketbeat.comABC Arbitrage SA Acquires New Holdings in Genmab A/S (NASDAQ:GMAB)ABC Arbitrage SA purchased a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 176,898 shares of the company's stock, valued at approximately $3,692,000. Other institutionaFebruary 16, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Upgraded at Leerink PartnersFebruary 16, 2025 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Raised to Strong-Buy at Leerink PartnrsFebruary 16, 2025 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Upgraded at Leerink PartnrsLeerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday.February 15, 2025 | marketbeat.comGenmab A/S (GMAB) Q4 2024 Earnings Conference Call TranscriptFebruary 14, 2025 | seekingalpha.comGenmab A/S 2024 Q4 - Results - Earnings Call PresentationFebruary 14, 2025 | seekingalpha.comLeerink Partners Upgrades Genmab A (GMAB)February 14, 2025 | msn.comWhy Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing TodayFebruary 13, 2025 | msn.comGenmab A/S (NASDAQ:GMAB) Stock Rating Upgraded by BNP ParibasBNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday.February 13, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Rating Increased to Outperform at Leerink PartnersLeerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research note on Thursday.February 13, 2025 | marketbeat.comIngalls & Snyder LLC Has $2.84 Million Stock Position in Genmab A/S (NASDAQ:GMAB)Ingalls & Snyder LLC reduced its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 37.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 136,059 shares of the company's stock after selling 82,424 shares during the period. Ingalls & Snyder LLC's holdings in GFebruary 13, 2025 | marketbeat.comNotice to Convene the Annual General Meeting of Genmab A/SFebruary 13, 2025 | globenewswire.comGenmab A/S (NASDAQ:GMAB) Releases Quarterly Earnings Results, Beats Expectations By $0.29 EPSGenmab A/S (NASDAQ:GMAB - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%.February 12, 2025 | marketbeat.comGenmab Files Annual Report with the U.S. Securities and Exchange CommissionFebruary 12, 2025 | globenewswire.comGenmab Publishes 2024 Annual ReportFebruary 12, 2025 | globenewswire.comRep. Josh Gottheimer Acquires Genmab A/S (NASDAQ:GMAB) StockRepresentative Josh Gottheimer (D-New Jersey) recently bought shares of Genmab A/S (NASDAQ:GMAB). In a filing disclosed on February 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Genmab A/S stock on January 16th. The trade occurred in the Representative's "MORFebruary 12, 2025 | marketbeat.comMirae Asset Global Investments Co. Ltd. Grows Position in Genmab A/S (NASDAQ:GMAB)Mirae Asset Global Investments Co. Ltd. lifted its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 229.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 49,727 shares of the company's stock after purchasing an additional 34,652 shares during the pFebruary 12, 2025 | marketbeat.comGenmab A/S (GMAB) Expected to Announce Earnings on WednesdayFebruary 11, 2025 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Hits New 1-Year Low - Here's WhyGenmab A/S (NASDAQ:GMAB) Sets New 52-Week Low - Here's What HappenedFebruary 10, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from BrokeragesGenmab A/S (NASDAQ:GMAB - Get Free Report) has been given an average rating of "Moderate Buy" by the nine analysts that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to theFebruary 8, 2025 | marketbeat.comGenmab A/S (GMAB) Expected to Announce Quarterly Earnings on WednesdayGenmab A/S (NASDAQ:GMAB) will be releasing earnings on Wednesday, February 12, Financial Modeling Prep reports.February 5, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Reaches New 1-Year Low - Here's WhyGenmab A/S (NASDAQ:GMAB) Hits New 52-Week Low - Should You Sell?February 3, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Sees Large Increase in Short InterestGenmab A/S (NASDAQ:GMAB - Get Free Report) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,730,000 shares, a growth of 25.4% from the December 31st total of 1,380,000 shares. Based on an average daily trading volume, of 1,240,000 shares, the short-interest ratio is presently 1.4 days. Approximately 0.3% of the company's shares are short sold.February 2, 2025 | marketbeat.comJPMorgan Chase & Co. Has $316,000 Stake in Genmab A/S (NASDAQ:GMAB)JPMorgan Chase & Co. reduced its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 53.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,943 shares of the company's stock after sJanuary 31, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Sets New 52-Week Low - Here's WhyGenmab A/S (NASDAQ:GMAB) Hits New 52-Week Low - Time to Sell?January 30, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Sees Large Volume Increase - Should You Buy?Genmab A/S (NASDAQ:GMAB) Sees Unusually-High Trading Volume - Should You Buy?January 29, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Sets New 52-Week Low - Here's What HappenedGenmab A/S (NASDAQ:GMAB) Hits New 52-Week Low - What's Next?January 28, 2025 | marketbeat.comHC Wainwright Forecasts Genmab A/S FY2024 EarningsGenmab A/S (NASDAQ:GMAB - Free Report) - Research analysts at HC Wainwright issued their FY2024 earnings per share estimates for shares of Genmab A/S in a note issued to investors on Thursday, January 23rd. HC Wainwright analyst R. Selvaraju expects that the company will earn $1.21 per share forJanuary 27, 2025 | marketbeat.comQ1 Earnings Estimate for Genmab A/S Issued By HC WainwrightGenmab A/S (NASDAQ:GMAB - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for Genmab A/S in a research report issued to clients and investors on Thursday, January 23rd. HC Wainwright analyst R. Selvaraju anticipates that the company will earn $0.18 per share for the quarter. HC WaJanuary 24, 2025 | marketbeat.comGrant of Restricted Stock Units and Warrants to Employees in GenmabJanuary 23, 2025 | globenewswire.comBrokers Offer Predictions for Genmab A/S FY2025 EarningsGenmab A/S (NASDAQ:GMAB - Free Report) - Equities research analysts at William Blair lowered their FY2025 earnings per share estimates for Genmab A/S in a research note issued to investors on Tuesday, January 21st. William Blair analyst M. Phipps now anticipates that the company will earn $1.38 pJanuary 23, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday.January 23, 2025 | marketbeat.comWhat To Expect From The Stock Market in 2025?January 23, 2025 | uk.finance.yahoo.comGenmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for 2024January 23, 2025 | finanznachrichten.deGenmab Announces Net Sales of DARZALEX® (daratumumab) for 2024January 22, 2025 | globenewswire.comGenmab (GMAB) Receives a Hold from Morgan StanleyJanuary 21, 2025 | markets.businessinsider.comGenmab A/S (NASDAQ:GMAB) Shares Gap Down - Here's What HappenedGenmab A/S (NASDAQ:GMAB) Shares Gap Down - Here's WhyJanuary 17, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Gap Up - Still a Buy?Genmab A/S (NASDAQ:GMAB) Shares Gap Up - Still a Buy?January 16, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Stock Unloaded Rep. Josh GottheimerRepresentative Josh Gottheimer (D-New Jersey) recently sold shares of Genmab A/S (NASDAQ:GMAB). In a filing disclosed on January 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Genmab A/S stock on December 16th. The trade occurred in the Representative's "MORGANJanuary 16, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Given Consensus Rating of "Moderate Buy" by AnalystsGenmab A/S (NASDAQ:GMAB - Get Free Report) has received an average rating of "Moderate Buy" from the ten research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have assignedJanuary 14, 2025 | marketbeat.comTD Cowen Sticks to Their Hold Rating for Genmab (GMAB)January 8, 2025 | markets.businessinsider.comGenmab’s Strategic Positioning and Promising Clinical Data Drive Buy Rating with $50 Price TargetJanuary 8, 2025 | markets.businessinsider.com Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address GMAB Media Mentions By Week GMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GMAB News Sentiment▼1.000.60▲Average Medical News Sentiment GMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GMAB Articles This Week▼185▲GMAB Articles Average Week Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today argenx News Today BioNTech News Today Teva Pharmaceutical Industries News Today Summit Therapeutics News Today Intra-Cellular Therapies News Today Viatris News Today Moderna News Today Dr. Reddy's Laboratories News Today Vaxcyte News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GMAB) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
